Markets:

Overview

News

Currencies

International

Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

62.14 +0.71 (+1.16%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 12, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics to Participate at Upcoming Investor Conferences

August 05, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Second Quarter 2026 Financial Results

August 04, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics to Report Second Quarter 2026 Financial Results

July 28, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

June 16, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 11, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

June 04, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

June 02, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

May 27, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 12, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics to Participate at Upcoming Investor Conferences

May 07, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

May 06, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

May 05, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports First Quarter 2026 Financial Results

May 04, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics to Report First Quarter 2026 Financial Results

April 27, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 14, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS

April 13, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

February 19, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

February 12, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 11, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit

February 04, 2026

From Travere Therapeutics, Inc.

Via Business Wire

TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

January 16, 2026

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS

January 13, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Provides Corporate Update and 2026 Outlook

January 12, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 11, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

November 06, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics to Participate at Upcoming Investor Conferences

November 04, 2025

From Travere Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.